Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema
Aim. To observe the clinical efficacy and safety of phacoemulsification surgery combined with intravitreal injection of conbercept in cataract patients with DME. Methods. This is a prospective clinical cohort study. Thirty-five cataract patients (49 eyes) with DME were divided into two groups. The o...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2021/8849730 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550238329503744 |
|---|---|
| author | Jing Wang Yuqi Liu Yiping Hu Lu Lu Kaili Tang Jinsong Zhang |
| author_facet | Jing Wang Yuqi Liu Yiping Hu Lu Lu Kaili Tang Jinsong Zhang |
| author_sort | Jing Wang |
| collection | DOAJ |
| description | Aim. To observe the clinical efficacy and safety of phacoemulsification surgery combined with intravitreal injection of conbercept in cataract patients with DME. Methods. This is a prospective clinical cohort study. Thirty-five cataract patients (49 eyes) with DME were divided into two groups. The observation group (23 eyes) underwent a cataract phacoemulsification surgery combined with intravitreal injection of conbercept 0.5 mg; the control group (26 eyes) underwent a cataract phacoemulsification surgery only. The visual acuity, central macular thickness (CMT), IOP, and anterior chamber flare were examined before surgery and 1 week and one month after surgery. Results. The UCVA and BCVA in Log MAR in the observation group were lower than those in the control group at 1 week (p=0.032; p=0.041) and 1 month (p=0.035; p=0.039), respectively, after the surgery. The CMT of the observation group changed from 492.7 ± 32.2 μm before surgery to 341.6 ± 59.9 μm one week after surgery and 374.8 ± 48.3 μm one month after surgery. The CMT of control group increased after surgery. There was no significant difference in IOP and flare between the two groups at all following times. Conclusion. In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation. |
| format | Article |
| id | doaj-art-b7b9ac232dde42f1a3eaa8923040d67e |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-b7b9ac232dde42f1a3eaa8923040d67e2025-02-03T06:07:17ZengWileyJournal of Ophthalmology2090-004X2090-00582021-01-01202110.1155/2021/88497308849730Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular EdemaJing Wang0Yuqi Liu1Yiping Hu2Lu Lu3Kaili Tang4Jinsong Zhang5Shenyang Aier Exellence Eye Hospital, Shenyang, ChinaThe Fourth Affiliated Hospital of China Medical University, Shenyang, ChinaThe Fourth Affiliated Hospital of China Medical University, Shenyang, ChinaThe Fourth Affiliated Hospital of China Medical University, Shenyang, ChinaShenyang Aier Exellence Eye Hospital, Shenyang, ChinaShenyang Aier Exellence Eye Hospital, Shenyang, ChinaAim. To observe the clinical efficacy and safety of phacoemulsification surgery combined with intravitreal injection of conbercept in cataract patients with DME. Methods. This is a prospective clinical cohort study. Thirty-five cataract patients (49 eyes) with DME were divided into two groups. The observation group (23 eyes) underwent a cataract phacoemulsification surgery combined with intravitreal injection of conbercept 0.5 mg; the control group (26 eyes) underwent a cataract phacoemulsification surgery only. The visual acuity, central macular thickness (CMT), IOP, and anterior chamber flare were examined before surgery and 1 week and one month after surgery. Results. The UCVA and BCVA in Log MAR in the observation group were lower than those in the control group at 1 week (p=0.032; p=0.041) and 1 month (p=0.035; p=0.039), respectively, after the surgery. The CMT of the observation group changed from 492.7 ± 32.2 μm before surgery to 341.6 ± 59.9 μm one week after surgery and 374.8 ± 48.3 μm one month after surgery. The CMT of control group increased after surgery. There was no significant difference in IOP and flare between the two groups at all following times. Conclusion. In patients with DME, undergoing a cataract surgery combined with intravitreal injection of conbercept is safe and effective for visual improvement and CMT declination with relatively fewer IOP and flare fluctuation.http://dx.doi.org/10.1155/2021/8849730 |
| spellingShingle | Jing Wang Yuqi Liu Yiping Hu Lu Lu Kaili Tang Jinsong Zhang Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema Journal of Ophthalmology |
| title | Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema |
| title_full | Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema |
| title_fullStr | Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema |
| title_full_unstemmed | Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema |
| title_short | Clinical Observation of Phacoemulsification Combined with Intravitreal Injection of Conbercept in Cataract Patients with Diabetic Macular Edema |
| title_sort | clinical observation of phacoemulsification combined with intravitreal injection of conbercept in cataract patients with diabetic macular edema |
| url | http://dx.doi.org/10.1155/2021/8849730 |
| work_keys_str_mv | AT jingwang clinicalobservationofphacoemulsificationcombinedwithintravitrealinjectionofconberceptincataractpatientswithdiabeticmacularedema AT yuqiliu clinicalobservationofphacoemulsificationcombinedwithintravitrealinjectionofconberceptincataractpatientswithdiabeticmacularedema AT yipinghu clinicalobservationofphacoemulsificationcombinedwithintravitrealinjectionofconberceptincataractpatientswithdiabeticmacularedema AT lulu clinicalobservationofphacoemulsificationcombinedwithintravitrealinjectionofconberceptincataractpatientswithdiabeticmacularedema AT kailitang clinicalobservationofphacoemulsificationcombinedwithintravitrealinjectionofconberceptincataractpatientswithdiabeticmacularedema AT jinsongzhang clinicalobservationofphacoemulsificationcombinedwithintravitrealinjectionofconberceptincataractpatientswithdiabeticmacularedema |